Savannah C. Partridge

Author

Also Known As

Elise Berman, Laura Martincich, Partridge, Savannah, Partridge, Savannah C., S Partridge, S. C. Partridge, S. Partridge, S.C. Partridge, Savannah C. Partridge, Savannah C Partridge

207

Publications

8.3K

Citations

H-Index

Concepts

All Affiliations

University of Washington Seattle Cancer Care Alliance University of California, San Francisco Fred Hutch Cancer Center University of Pennsylvania

About

Savannah C. Partridge is an author at University of Washington specializing in radiology, medical imaging, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	17	19	1.3K
2	Medicine	16	17	1.2K
3	Engineering	12	12	522
4	Biomedical Engineering	2	2	115
5	Social Sciences	1	1	61

Savannah C. Partridge

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Accuracy of MR Imaging for Revealing Residual Breast Cancer in Patients Who Have Undergone Neoadjuvant Chemotherapy Savannah C. Partridge, Jessica Gibbs, Ying Lü, American Journal of Roentgenology	2002	339
MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival Savannah C. Partridge, Jessica Gibbs, Ying Lü, American Journal of Roentgenology	2005	274
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial Savannah C. Partridge, Zheng Zhang, David C. Newitt, Radiology Breast OncologyNeoadjuvant ChemotherapyMedical ImagingOncologic ImagingMedicine	2018	274
Quantitative Diffusion-Weighted Imaging as an Adjunct to Conventional Breast MRI for Improved Positive Predictive Value Savannah C. Partridge, Wendy B. DeMartini, Brenda F. Kurland, American Journal of Roentgenology	2009	267
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL Nola M. Hylton, Constantine Gatsonis, Mark Rosen, Radiology	2015	265
Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk? Brian N. Dontchos, Habib Rahbar, Savannah C. Partridge, Radiology	2015	211
Differential diagnosis of mammographically and clinically occult breast lesions on diffusion‐weighted MRI Savannah C. Partridge, Wendy B. DeMartini, Brenda F. Kurland, Journal of Magnetic Resonance Imaging	2010	172
Apparent Diffusion Coefficient Values for Discriminating Benign and Malignant Breast MRI Lesions: Effects of Lesion Type and Size Savannah C. Partridge, Christiane Mullins, Brenda F. Kurland, American Journal of Roentgenology	2010	172
2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution Savannah C. Partridge, A. Timothy, Michael O’Doherty, Annals of Oncology Positron Emission TomographyPretreatment StagingOncologic ImagingMedical ImagingPatient Management	2000	171
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging Lisa J. Wilmes, Maria G. Pallavicini, L. Fleming, Magnetic Resonance Imaging Vascular PermeabilityNovel InhibitorAngiogenesisMedicineReceptor Tyrosine Kinase	2007	154

Page 1